Elizabeth Berry-Kravis is professor of child neurology at Rush University Medical Center in Chicago.
Elizabeth Berry-Kravis
Professor
Rush University Medical Center
From this contributor
Analysis offers new hope for failed fragile X drug
Eye tracking shows that mavoglurant, a once-abandoned experimental drug for fragile X syndrome, enters the brain and boosts social interest, says Elizabeth Berry-Kravis.
Analysis offers new hope for failed fragile X drug
Questions for Elizabeth Berry-Kravis: Dodging mouse traps
A mouse model of fragile X syndrome lacks a key feature of the condition, prompting researchers to look for other ways to test treatments.
Questions for Elizabeth Berry-Kravis: Dodging mouse traps
Questions for Elizabeth Berry-Kravis: Measuring drug effects
Drugs designed to treat fragile X syndrome have yet to show substantial benefits in people. But rather than abandon them, child neurologist Elizabeth Berry-Kravis suggests a new way to measure their effectiveness.
Questions for Elizabeth Berry-Kravis: Measuring drug effects
Explore more from The Transmitter
Securing the academic pipeline amid uncertain U.S. funding climate
Finding creative ways to keep early-career researchers in academia—for example, through part-time roles—can help the field weather the storm.
Securing the academic pipeline amid uncertain U.S. funding climate
Finding creative ways to keep early-career researchers in academia—for example, through part-time roles—can help the field weather the storm.
Let’s teach neuroscientists how to be thoughtful and fair reviewers
Blanco-Suárez revamped the traditional journal club by developing a course in which students peer review preprints alongside the published papers that evolved from them.
Let’s teach neuroscientists how to be thoughtful and fair reviewers
Blanco-Suárez revamped the traditional journal club by developing a course in which students peer review preprints alongside the published papers that evolved from them.
New autism committee positions itself as science-backed alternative to government group
The Independent Autism Coordinating Committee plans to meet at the same time as the U.S. federal Interagency Autism Coordinating Committee later this month—and offer its own research agenda.
New autism committee positions itself as science-backed alternative to government group
The Independent Autism Coordinating Committee plans to meet at the same time as the U.S. federal Interagency Autism Coordinating Committee later this month—and offer its own research agenda.